FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype

FDA News, New FDA Approvals
March 9, 2020
A+ A-
Email Print

Article Link: FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype

Ridgefield, Conn., March 9, 2020 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) as the first treatment for people with chronic fibrosing interstitial lung diseases…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post